论文部分内容阅读
The new position statement of the American Diabetes Association and the European Association for the Study of Diabetes on the management of type 2 diabetes mellitus represents a paradigm shift in our understanding of antidiabetic treatment.It emphasises the necessity to individualise management based on patient needs.Glycaemic targets should also be pursued on an individualised basis.New therapeutic combinations are discussed,and the uncertainty surrounding the ideal choice is acknowledged.Above all,it is the mindful and experienced clinician who will implement the best available evidence towards flexible and efficacious treatment.Some areas of uncertainty may ensue,but it is expected that the new position statement will improve patient healthcare and treatment satisfaction.This now remains to be seen in practice.
The new position statement of the American Diabetes Association and the European Association for the Study of Diabetes on the management of type 2 diabetes mellitus represents a paradigm shift in our understanding of antidiabetic treatment. Weight of the necessity to individualise management based on patient needs. Glycymic The targets should also be pursued on an individual basis .New therapeutic combinations are discussed, and the uncertainty surrounding the ideal choice is acknowledged. Abbove all, it is the mindful and experienced clinician who will implement the best available evidence for flexible and efficacious treatment.Some areas of uncertainty may ensue, but it is expected that the new position statement will improve patient healthcare and management satisfaction. This now remains to be seen in practice.